Literature DB >> 19140212

Establishment of a cut-point value of serum TNF-alpha levels in the metabolic syndrome.

Carmen M Gurrola-Díaz1, Sergio Sánchez-Enriquez, Edith Oregon-Romero, Pedro M García-López, Pedro Garzón de la Mora, Blanca E Bastidas-Ramírez, Mercedes González-Hita, José F Muñoz-Valle.   

Abstract

Cardiovascular diseases and type 2 diabetes are the major causes of mortality in Mexico. Metabolic syndrome (MS) is a cluster of factors that increase the risk to develop such diseases. Previous studies have shown that MS is associated with high tumor necrosis factor (TNF-alpha) levels. In fact, TNF-alpha has been proposed to be a useful marker for clinical diagnosis of inflammation at an early stage. Therefore, we analyzed TNF-alpha concentrations in Mexican individuals with or without MS and related these levels to the associated MS components. Clinical, anthropometric, and biochemical data were analyzed in 41 healthy and 39 MS individuals. Individuals were similarly grouped by age and gender.The serum TNF-alpha levels measured by a highly sensitive enzyme-linked immunosorbent assay (ELISA) kit were increased significantly in MS subjects compared with healthy individuals (P<0.001). The assay showed 78.1% sensitivity and 61.5% specificity with a cut-point level of 1.36 pg/mL. TNF-alpha levels higher than the cut-point value were correlated with insulin resistance indices. These findings support the hypothesis that serum TNF-alpha concentration could be a useful marker for early MS diagnosis. Nevertheless, we suggest the establishment of specific cut-point values in each studied population to evaluate potential clinical applications. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19140212      PMCID: PMC6649136          DOI: 10.1002/jcla.20289

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  24 in total

1.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

Review 2.  Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence.

Authors:  Earl S Ford
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

3.  Hyperlipidaemias and serum cytokines in patients with coronary artery disease.

Authors:  Katarzyna Mizia-Stec; Barbara Zahorska-Markiewicz; Tadeusz Mandecki; Joanna Janowska; Andrzej Szulc; Ewa Jastrzekbska-Maj; Zbigniew Gasior
Journal:  Acta Cardiol       Date:  2003-02       Impact factor: 1.718

4.  TNF-alpha in the development of insulin resistance and other disorders in metabolic syndrome.

Authors:  Simona Gwozdziewiczová; Radka Lichnovská; Rabha Ben Yahia; Rudolf Chlup; Jirí Hrebícek
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2005-06       Impact factor: 1.245

5.  Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.

Authors:  Iris J Jonkers; Martina F Mohrschladt; Rudi G Westendorp; Arnoud van der Laarse; Augustinus H Smelt
Journal:  Am J Med       Date:  2002-03       Impact factor: 4.965

Review 6.  Inflammatory pathways and insulin action.

Authors:  G S Hotamisligil
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12

7.  The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome--an analysis by structural equation modelling.

Authors:  J C N Chan; J C K Cheung; C D A Stehouwer; J J Emeis; P C Y Tong; G T C Ko; J S Yudkin
Journal:  Int J Obes Relat Metab Disord       Date:  2002-07

8.  The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase.

Authors:  P A Kern; M Saghizadeh; J M Ong; R J Bosch; R Deem; R B Simsolo
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

9.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.

Authors:  D Aderka; H Engelmann; Y Maor; C Brakebusch; D Wallach
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

10.  High prevalence of metabolic syndrome in Mexico.

Authors:  Carlos A Aguilar-Salinas; Rosalba Rojas; Francisco J Gómez-Pérez; Victoria Valles; Juan Manuel Ríos-Torres; Aurora Franco; Gustavo Olaiz; Juan A Rull; Jaime Sepúlveda
Journal:  Arch Med Res       Date:  2004 Jan-Feb       Impact factor: 2.235

View more
  2 in total

1.  Self-reported racial/ethnic discrimination and bronchodilator response in African American youth with asthma.

Authors:  Sonia Carlson; Luisa N Borrell; Celeste Eng; Myngoc Nguyen; Shannon Thyne; Michael A LeNoir; Nadine Burke-Harris; Esteban G Burchard; Neeta Thakur
Journal:  PLoS One       Date:  2017-06-13       Impact factor: 3.240

2.  THE ASSOCIATION BETWEEN PRO AND ANTI-INFLAMMATORY MARKERS WITH THE COMPONENTS OF METABOLIC SYNDROME.

Authors:  S Kir; K Ekiz; H Alacam; R Turkel; E Koroglu; B L Altintop
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.